- Home
- ACRV vs FLL Comparison
ACRV vs FLL Comparison
Compare ACRV & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRV | FLL |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.0M | 77.7M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACRV | FLL |
|---|---|---|
| Price | $2.13 | $2.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $11.67 | $4.00 |
| AVG Volume (30 Days) | ★ 336.3K | 124.8K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.13 | 3.45 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $302,376,000.00 |
| Revenue This Year | N/A | $7.54 |
| Revenue Next Year | $568.17 | $6.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.53 |
| 52 Week Low | $1.27 | $1.96 |
| 52 Week High | $3.56 | $3.61 |
Technical Indicators
Market Signals| Indicator | ACRV | FLL |
|---|---|---|
| Relative Strength Index (RSI) | 55.09 | 41.74 |
| Support Level | $1.38 | $1.99 |
| Resistance Level | $2.15 | $2.74 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 25.79 | 25.00 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins. Geographically, it operates in United States.